Jiangxi Synergy Pharmaceutical (300636.SZ): Vildagliptin tablets obtain drug registration certificate.

14/01/2025

GMT Eight

Jiangxi Synergy Pharmaceutical (300636.SZ) announced that the company recently received the Drug Registration Certificate for Vildagliptin Tablets issued by the National Medical Products Administration (NMPA). Vildagliptin Tablets are used for the treatment of type 2 diabetes.

On January 13th, HSBC Holdings (00005) spent 54.84 million pounds to buy back 690.85 million shares.

On January 13th, STANCHART (02888) spent 5.31 million to repurchase 52,450 shares.

Contact: contact@gmteight.com

Jiangxi Synergy Pharmaceutical (300636.SZ): Vildagliptin tablets obtain drug registration certificate.

RECOMMEND

Spring Airlines (601021.SH): The total number of passengers carried in December was 2.3415 million, a month-on-month increase of 7.80%.

Shenzhen Bingchuan Network (300533.SZ) issues a forecasted loss, expecting a loss of 240 million to 340 million yuan in 2024, turning from a profit to a loss year-on-year.

Shareholder Feng Weizu of Wuxi New Hongtai Electrical Technology (603016.SH) has collectively reduced his holdings in the company by 105,500 shares.